SF3A3 and neoplasm: The therapeutic potential of SF3A3 inhibition is further validated using patient‐derived tumor‐like cell clusters (PTCs), where PEITC and the c‐FOS inhibitor T‐5224 exhibit synergistic effects in suppressing EC.